Results 71 to 80 of about 12,722 (192)

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Efficacy and safety of sacubitril‐valsartan in heart failure: a meta‐analysis of randomized controlled trials

ESC Heart Failure, 2020
Aims Sacubitril‐valsartan has been shown to have superior effects over angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure (HF) and hypertension.
Hongzhou Zhang, Tieqiu Huang, Wen Shen, Xiuxiu Xu, Pingping Yang, Dan Zhu, Haiyang Fang, Hongbing Wan, Tao Wu, Yanqing Wu, Qinghua Wu   +10 more
doaj   +1 more source

Sacubitril/valsartan: research progress of multi-channel therapy for cardiorenal syndrome

Frontiers in Pharmacology, 2023
Cardiorenal syndrome (CRS) results from complex interaction between heart and kidneys, inducing simultaneous acute or chronic dysfunction of these organs.
Shuangcui Wang, Yuli Wang, Yun Deng, Jiaqi Zhang, Xijuan Jiang, Jianchun Yu, Jiali Gan, Wenyun Zeng, Maojuan Guo   +8 more
doaj   +1 more source

Monitoring of biomarkers in heart failure. [PDF]

, 2019
The role of biomarkers is increasingly recognized in heart failure (HF) management, for diagnosis, prognostication, and screening of high-risk patients.
Agewall, Agewall, Agewall, Agostoni, Andrew J S Coats, Ather, Bayes-Genis, Bhambhani, Binas, Broch, Demissei, Felker, Giuseppe M C Rosano, Graham, Greene, Hallén, Harjola, Hoedemaker, Ilaria Spoletini, Januzzi, Januzzi, Ky, McCarthy, Michele Senni, Mueller, Nadar, O'Meara, Pareek, Paul, Peacock, Perk, Ponikowski, Rastogi, Salmonson, Sarhene, Sato, Schneider, Shah, Squire, Stenemo, Tamargo, Troughton, Welsh, Xue   +43 more
core   +1 more source

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure

ESC Heart Failure, 2020
Aims Large‐scale clinical trials have demonstrated clinical benefits of sacubitril–valsartan in symptomatic heart failure with reduced ejection fraction patients (PARADIGM‐HF), with potential benefits in patients hospitalized for acute decompensated ...
David Carballo, Jérôme Stirnemann, Nicolas Garin, Chistophe Marti, Jacques Serratrice, Sebastian Carballo   +5 more
doaj   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study

Indian Heart Journal, 2020
Objectives: To determine efficacy and safety of sacubitril/valsartan compared with enalapril in Indian patients of PARADIGM-HF trial. Methods: A randomized, double-blind, active-controlled, phase III sub-study (NCT01035255) was conducted between April ...
Anil Ranjeetmal Jain, Rakesh Kumar Aggarwal, Nanyam Srinivas Rao, Gauri Billa, Shankar Kumar   +4 more
doaj   +1 more source

Natriuretic Peptides in the Cardiovascular System. Multifaceted Roles in Physiology, Pathology and Therapeutics [PDF]

, 2019
The natriuretic peptides (NPs) family includes a class of hormones and their receptors needed for the physiological control of cardiovascular functions. The discovery of NPs provided a fundamental contribution into our understanding of the physiological ...
Rubattu, Speranza, Volpe, Massimo
core   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source